StemCell Therapy

Abeona Therapeutics Inc (ABEO) is around the bottom of the Biotechnology industry according to InvestorsObserver. ABEO received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Abeona Therapeutics Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Abeona Therapeutics Inc (ABEO) stock has fallen -5.46% while the S&P 500 is up 1.25% as of 2:03 PM on Wednesday, Sep 30. ABEO is down -$0.06 from the previous closing price of $1.11 on volume of 4,933,979 shares. Over the past year the S&P 500 is higher by 14.86% while ABEO is down -53.95%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

More:
Is Abeona Therapeutics Inc (ABEO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

This entry was posted on October 4, 2020 at 11:01 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |